USFDA approved Facility 268 KL capacity 5 times present capacity Existing Contract Manufacturing for Pfizer Immediate products for US Markets Due Diligence on Acquisition of majority stake Further Capex into Co. through rights issue Merger into Co. 9-24 months
A strong entry strategy for the rest of European Union(EU),
New product developments and increased product introductions in the future.
Leveraging manufacturing and R&D capabilities of Wanbury.
Launch of pure generic drugs in Spain
The acquisition will be financed by a combination of internal accruals over the period of three years and term loans. Wanbury Limited has set a vision of Rs 1000 crores market capitalization by 2009.